AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2016
Mar 25, 2016
33148_dirs_2016-03-24_a2e49265-ee09-4086-8eed-c48a04136eca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2016-03-22
Reporting Person: McVicar William K. (See Remarks)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-03-22 | Stock Options (Right to Buy) | $7.56 | A | 135000 | Acquired | 2026-03-21 | Common Stock (135000) | Direct |
Footnotes
F1: The stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). 25% of the options granted shall vest on the one year anniversary of January 1, 2016 and 1/36th of the remaining option grant shall vest on each monthly anniversary thereafter, subject to continued service through such dates.
F2: As previously reported on June 26, 2015, the Reporting Person was granted a stock option award under the Plan. The total beneficially owned derivative securities following the grant inadvertently included securities of a separate class, and accordingly such previously inadvertently reported shares are now properly excluded. In addition, the Price of Derivative Security reported on the June 26, 2015 Form 4 was inadvertently reported as $5.03 when it should have properly been recorded as $0.